

1 MWANGI AND OTHERS HUMAN MILK OLIGOSACCHARIDES AND MALARIA

2 **Title:** Sex-dependent associations between human milk oligosaccharides and malaria outcomes in
3 breastfeeding Ugandan children

4 **Authors:** Victor Irungu Mwangi^{1,*}, Tonny Jimmy Owalla², Sara Moukarzel^{3,4}, Emmanuel Okurut², Chloe
5 Yonemitsu³, Lars Bode^{3,4}, and Thomas G. Egwang²

6
7 **Author affiliations:** ¹Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do
8 Amazonas (UEA), Manaus, AM, Brazil; ²Med Biotech Laboratories, Kampala, Uganda; ³Department of
9 Pediatrics, Division of Neonatology, University of California San Diego, La Jolla, California, United States
10 of America; ⁴Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence (MOMI
11 CORE), University of California San Diego, La Jolla, California, United States of America.

12
13 **Key words**

14 Human milk oligosaccharides, malaria, breastfeeding children

15 * Corresponding Author: mwangiv@gmail.com;

16
17 **Abstract**

18 Human milk oligosaccharides (HMOs), whose compositions vary between secretor and non-secretor
19 mothers, protect breastfeeding children against various diseases. We investigated the relationship between
20 HMOs in Ugandan secretor mothers and malaria outcomes in their children. Malaria outcomes in
21 breastfeeding children followed up over seven months were classified as malaria-free and asymptomatic,
22 mild, or severe malaria. A single human milk sample collected from each mother was analyzed for HMOs.
23 Significantly higher 2'fucosyllactose (2'FL) and lacto-N-fucopentaose I (LNFP I) concentrations were
24 observed in mothers of malaria-free children, and significantly higher lacto-N-tetraose (LNT) concentrations
25 were observed in mothers of children with asymptomatic malaria. Concentrations of five HMOs, 3-

26 fucosyllactose (3 FL), 3'-sialyllactose (3'SL), difucosyllactose (DFLac), lacto-N-fucopentaose II (LNFP II),
27 and sialyllacto-*N*-tetraose b (LSTb); and two HMOs, difucosyllacto-*N*-tetrose (DFLNT) and fucosyllacto-*N*-
28 hexaose (FLNH) were significantly higher in mothers of malaria-infected children and children with severe
29 malaria, respectively. Sex-dependent associations were observed for some HMOs.

30

31

Methods, Results & Discussion

32

Breastfeeding protects children against malaria by mechanisms which are poorly understood [1].

33

Human milk oligosaccharides (HMOs), representing the third most abundant component of human milk,

34

protect breastfeeding children against diseases [2]. HMO concentrations vary between secretor and non-

35

secretor mothers [3,4] who constitute approximately 80 % and 20 % of Ugandan mothers, respectively [5].

36

Secretor mothers have an active fucosyltransferase 2 (FUT2) making their milk highly abundant in FUT-2

37

dependent HMOs like 2'-fucosyllactose (2'FL) and lacto-*N*-fucopentaose I (LNFP I); non-secretor mothers

38

with an inactive FUT2 have low milk concentrations of FUT2-dependent HMOs [1,2]. Here, we investigated

39

the relationship between HMOs in 99 Ugandan secretor mothers and malaria outcomes in their breastfeeding

40

children (**Supplementary Table 1**). Non-secretor mother-child pairs were not included because of the small

41

sample size. Children were followed up between March and September 2018 for malaria infection and

42

clinical episodes during clinic visits. Malaria diagnosis was by CareStart malaria Pf (HRP-2) rapid diagnostic

43

test (Access Bio, NJ, USA). Malaria-free (MF) children were consistently malaria-negative during 8 clinic

44

visits for other ailments. Children with asymptomatic malaria (AM) were malaria-positive with no symptoms

45

or fever. Children with mild malaria (MM) were malaria-positive with non-specific symptoms like vomiting,

46

diarrhea, poor feeding and fever (≥ 37.5 °C). Finally, children with severe malaria (SM) were malaria-positive

47

with other symptoms including respiratory distress and severe anemia requiring blood transfusion according

48

to the World Health Organization definition [6]. Children with AM or MM received artemether-lumefantrine

49 (Coartem); those with SM received intravenous quinine or rectal artesunate according to national treatment
50 guidelines.

51 A single human milk sample was collected from each mother in March 2018 and analyzed for 19
52 HMOs by high performance liquid chromatography (HPLC) as described [7]. Human milk was spiked with
53 raffinose as an internal standard. Absolute concentrations were calculated based on standard response curves
54 for each annotated HMO. The total concentration of HMOs was calculated as the sum of the annotated
55 oligosaccharides and the relative abundance of each HMO was calculated. HMO-bound fucose and HMO-
56 bound sialic acid were calculated on a molar basis. Simpson's Diversity index was calculated based on
57 relative abundance of HMOs. Children with laboratory-confirmed malaria were designated malaria infected
58 (MI = AM+MM+SM; n=35); and those who experienced clinical malaria were grouped as MM+SM (n=19).
59 Associations between HMO concentrations and malaria outcomes in all children and separately in males and
60 females were assessed by the Mann-Whitney U and Welch t-tests.

61 We first compared HMOs between mothers of malaria-free (n=64) and malaria-infected (MF versus
62 MI) children. Higher 2'FL, LNFP I, total HMOs and HMO-bound fucose (HMO-Fuc) concentrations were
63 observed in mothers of MF children (**Figure 1A**). Although LNFP I concentrations decrease during lactation
64 (5, 8), the median LNFP I concentration during late lactation was significantly higher in mothers of malaria-
65 free children (1247.8 (537.4-2135.0) nmol/mL versus 450.0 (330.6-1417.2) nmol/mL; P = 0.006). By
66 contrast, higher 3'sialyllactose (3'SL), 3-fucosyllactose (3FL), difucosyllactose (DFLac), lacto-N-
67 fucopentaose II (LNFP II) and sialyllacto-N-tetraose b (LSTb) concentrations and the diversity index
68 (reflecting variety in HMOs) were observed in mothers of MI children (**Figure 1B**). We next compared
69 HMOs between mothers of children with AM and children with clinical malaria (AM versus MM+SM).
70 Lacto-N-tetraose (LNT) concentrations were higher in mothers of AM children (**Figure 1C; Supplementary**
71 **Table 2**). We then compared HMOs between mothers of children with mild malaria (MM) and children with
72 severe malaria (SM). Difucosyllacto-N-tetraose (DFLNT), fucosyllacto-N-hexaose (FLNH) and HMO-Fuc

73 concentrations were higher in mothers of SM children (**Figure 1D, Supplementary Table 3**). Finally, since
74 MF and AM outcomes might overlap, we compared HMOs between mothers of MF children and children
75 with AM. Diversity and LNT concentrations were higher in mothers of AM but not MF children while 2'FL,
76 LNFPI, total HMOs and HMO-Fuc concentrations were higher in mothers of MF but not AM children
77 (**Figure 1E and F, Supplementary Table 4**).

78 The relationships between HMOs and malaria outcomes were re-analyzed by children's sex. Higher
79 2'FL and HMO-Fuc concentrations in mothers of MF children were observed for females (**Figure 2A**).
80 Higher diversity and LSTb concentrations in mothers of MI children were observed for females, while higher
81 LNFP II concentrations in mothers of MI children were observed for males (**Figure 2B**). Second, higher LNT
82 concentrations in mothers of children with AM were observed for males while higher HMO-Fuc
83 concentrations in mothers of children with MM+SM were also observed for males (**Figure 2C**). Finally,
84 higher diversity and LNT concentrations in mothers of children with AM and higher LNFP I and HMO-Fuc
85 concentrations in mothers of MF children were observed for females (**Figure 2D and E**). The analyses for
86 all HMOs by sex are presented in **Supplementary Tables 5-7**. Analysis by sex was not done for malaria
87 severity because of small sample sizes.

88 It is remarkable that HMOs in milk collected at a single time point from mothers at different lactation
89 stages were associated with malaria outcomes in children during follow up. From published [8] and our own
90 studies [5], eight of these HMOs remain unchanged or increase in concentration throughout lactation. It is
91 plausible that the concentrations of these HMOs at the single sampling mirrored those in mothers during
92 follow up. Although LNFP I was reduced in late lactation [821.3 (373.8-1941.4) nmol/mL at > 6 months
93 versus 1586.7 (620.5-2475.0) nmol/mL at \leq 6 months; $P = 0.048$], it was still associated with the malaria-
94 free status. This raises the possibility that HMOs which decrease in early lactation may still have an effect
95 on disease risk in breastfeeding children in late lactation.

96 Our data confirm previous reports that fucose-bound HMOs protected children against infectious
97 diseases [1,2] and extends this protection to malaria. Concentrations of 2'FL and LNFP1, with an α 1-2 fucose
98 linkage, were significantly higher in mothers of malaria-free but not malaria-infected children. By contrast,
99 LNFP1 and DFLac, with α 1-3 and α 1-4 fucose linkages, were significantly higher in mothers of malaria-
100 infected children. Our data support previous reports linking higher concentrations of α 1-2-fucosylated HMOs
101 to a lower incidence of diarrhea [9,10], zero sick days [11] and lower infant mortality in HIV-exposed infants
102 [12] and higher concentrations of α 1-3 fucosylated HMOs to sick days [11]. Moreover, significantly higher
103 concentrations of LNT in mothers of children with asymptomatic malaria suggest that it might be associated
104 with malaria clinical immunity. Additionally, high concentrations of DFLNT and FLNH were observed in
105 mothers of children with severe but not mild malaria; previous studies have not reported associations between
106 HMOs and disease severity in children. Finally, significant differences in HMO concentrations between
107 mothers of children with asymptomatic malaria and malaria-free children (**Figure 1E and F; Figure 2D and**
108 **E**) suggest that these malaria outcomes do not overlap in this study.

109 To the best of our knowledge, this is the first study to report significant sex-dependent associations
110 between HMOs and malaria outcomes in children from a malaria-endemic region. However, the mechanisms
111 by which HMOs influence malaria outcomes in children in a sex-dependent manner remain unknown. Some
112 HMOs reach the systemic circulation after ingestion [13] where they engage innate immune cells implicated
113 in malaria protection and disease [14,15,16]. HMOs also act as soluble decoy receptors which pre-empt
114 pathogen attachment to host cells [2]. Finally, HMOs induce specific microbiota which are important for the
115 development of immunity [2,17] and sex differences in microbiota composition [18] and innate immune
116 responses have been reported in malaria patients [19]. Mechanistic studies of HMOs and malaria outcomes
117 in children must be undertaken to obtain useful insights about the mechanisms of breastfeeding-mediated
118 protection.

119 This study has several limitations. First, associations between HMO blood concentrations in children
120 and malaria outcomes were not investigated. Second, the sample sizes were small especially when malaria
121 outcomes were stratified by children's sex and disease severity. However, this limitation does not negate the
122 significant differences in concentrations and composition of HMOs between mothers of children with
123 different malaria outcomes. The confirmation of prior literature linking α 1-2-fucosylated HMOs and α 1-3-
124 or α 1-4-fucosylated HMOs to protection and disease in children [9, 10,11, 12] validates our findings. Third,
125 a single milk sample, rather than longitudinal milk samples, was collected from each mother at the same time
126 point for measuring HMO concentrations. This limitation is mitigated by the observed significant
127 associations between HMO concentrations and malaria outcomes in children and the fact that the
128 concentrations of eight of these HMOs remain constant or increase during lactation (8). Fourth, the malaria-
129 free status was not confirmed by a more sensitive molecular diagnostic test to distinguish it from
130 asymptomatic malaria with low parasitemias. However, comparisons of LNT, 2'FL and LNFP I
131 concentrations between mothers of malaria-free children and children with asymptomatic malaria suggest
132 that these malaria outcomes do not overlap. Finally, our results are not generalizable to children of non-
133 secretor mothers with different HMO concentrations and composition [3,4]. These limitations will be
134 addressed in future longitudinal studies of breastfeeding secretor and non-secretor mother-child pairs.

135 In conclusion, our observational study demonstrated significant sex-dependent associations between
136 malaria outcomes in breastfed children with concentrations of α 1-2-fucosylated HMOs, α 1-3- or α 1-4-
137 fucosylated HMOs, and sialylated HMOs in milk of Ugandan secretor mothers.

138 **Ethical Consideration:** The Uganda National Council for Science and Technology and the Research
139 Ethics Committee of the Vector Division, Ministry of Health, approved the original HD4MC study. All
140 mothers who donated milk samples and brought infants to the study clinic for malaria monitoring and health
141 assessment signed or thumb-printed an informed consent form.

142 **Acknowledgements:** We are grateful to the Ugandan mother-children pairs for their participation.

143 We would like to thank the clinical and laboratory staff of Med Biotech Laboratories at St Anne HC III,
144 Usuk subcounty in Katakwi District, Uganda.

145 **Financial support:** Thomas Egwang received funding from the Global Innovation Fund and
146 Grand Challenges Canada. Lars Bode is UC San Diego Chair of Collaborative Human Milk Research
147 endowed by the Family Larsson-Rosenquist Foundation (FLRF), Switzerland. The funders played no role
148 in the study design, data collection and analysis nor in the preparation of the manuscript and decision to
149 publish this paper.

150 **Authors' Current addresses:** Victor Irungu Mwangi: Programa de Pós-Graduação em Medicina
151 Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil; Tonny Owalla, Emmanuel
152 Okurut, and Thomas G. Egwang: Med Biotech Laboratories, P.O. Box 9364, Kampala, Uganda; Sara
153 Moukarzel, Chloe Yonemitsu, and Lars Bode: University of California San Diego, La Jolla, California,
154 United States of America. E-mail addresses: tgegwang@gmail.com, owallatonny@gmail.com,
155 okurutemmanuel1@gmail.com, mwangiv@gmail.com, cyonemit@ucsd.edu,
156 smoukarzel@health.ucsd.edu, lbode@health.ucsd.edu.

157 158 159 **References**

- 160 1. Brazeau NF, Tabala M, Kiketa L, et al. Exclusive Breastfeeding and Clinical Malaria Risk in 6-Month-
161 Old Infants: A Cross-Sectional Study from Kinshasa, Democratic Republic of the Congo. *Am J Trop Med*
162 *Hyg.* 2016;95(4):827-830
- 163 2. Bode L 2012. Human milk oligosaccharides: Every baby needs a sugar mama. *Glycobiology* 22 :1147-
164 62.

- 165 3. Kunz C, Meyer C, Collado MC, et al. 2017. Influence of Gestational Age, Secretor, and Lewis Blood
166 Group Status on the Oligosaccharide Content of Human Milk. *J Pediatr Gastroenterol Nutr.* 64:789-98.
- 167 4. Totten SM, Zivkovic AM, Wu S, et al. 2012. Comprehensive profiles of human milk oligosaccharides
168 yield highly sensitive and specific markers for determining secretor status in lactating mothers. *J Proteome*
169 *Res.* 11:6124-33.
- 170 5. Owalla et al. 2023. The effect of non-genetic determinants of human milk oligosaccharide profiles in milk
171 of Ugandan mothers. MS submitted.
- 172 6. Imbert P, Gérardin P, Rogier C, et al. 2002. Severe falciparum malaria in children: a comparative study of
173 1990 and 2000 WHO criteria for clinical presentation, prognosis and intensive care in Dakar, Senegal. *Trans*
174 *R Soc Trop Med Hyg.* 96:278-81.
- 175 7. Berger PK, Hampson HE, Schmidt KA, et al. 2023. Stability of Human-Milk Oligosaccharide
176 Concentrations Over 1 Week of Lactation and Over 6 Hours Following a Standard Meal. *J Nutr.*
177 *14;152:2727-33.*
- 178 8. Plows JF, Berger PK, Jones RB, et al. 2021. Longitudinal Changes in Human Milk Oligosaccharides
179 (HMOs) Over the Course of 24 Months of Lactation. *J Nutr.* 151:876-82.
- 180 9. Newburg DS, Ruiz-Palacios GM, Altaye M, et al. 2004. Innate protection conferred by fucosylated
181 oligosaccharides of human milk against diarrhea in breastfed infants. *Glycobiology.* 14:253–63.
- 182 10. Morrow AL, Ruiz-Palacios GM, Altaye M, et al. 2004. Human milk oligosaccharide blood group epitopes
183 and innate immune protection against campylobacter and calicivirus diarrhea in breastfed infants. *Adv Exp*
184 *Med Biol.* 554:443–46.
- 185 11. Davis JCC, Lewis ZT, Krishnan S, et al. 2017. Growth and Morbidity of Gambian Infants are
186 Influenced by Maternal Milk Oligosaccharides and Infant Gut Microbiota. *Sci Rep.* 7:40466.
- 187 12. Kuhn L, Kim H-Y, Hsiao L, et al. 2015. Oligosaccharide composition of breast milk influences survival
188 of uninfected children born to HIV-infected mothers in Lusaka, Zambia. *J Nutr.* 145:66–72.

- 189 13. Goehring KC, Kennedy AD, Prieto PA, Buck RH. 2014. Direct evidence for the presence of human
190 milk oligosaccharides in the circulation of breastfed infants. *PLoS One*. 2014;9(7):e101692.
- 191 14. Triantis V, Bode L and van Neerven RJJ. 2018. Immunological Effects of Human Milk Oligosaccharides.
192 *Front. Pediatr*. 6:190.
- 193 15. Chua CL, Brown G, Hamilton JA, Rogerson S, Boeuf P. 2013. Monocytes and macrophages
194 in malaria: protection or pathology? *Trends Parasitol*. 29:26-34.
- 195 16. Dobbs KR, Crabtree JN, Dent AE. 2020. Innate immunity to malaria-The role of monocytes.
196 *Immunol Rev*. 293:8-24.
- 197 17. Berger B, Porta N, Foata F, et al. 2020. Linking Human Milk Oligosaccharides, Infant Fecal
198 Community Types, and Later Risk To Require Antibiotics. *mBio*. 2020;11(2):e03196-19.
- 199 18. Valeri F, Endres K. 2021. How biological sex of the host shapes its gut microbiota. *Front*
200 *Neuroendocrinol*. 61:100912.
- 201 19. Kanoi BN, Egwang TG. 2021. Sex differences in concentrations of HMGB1 and numbers of
202 pigmented monocytes in infants and young children with malaria. *Parasitol Int*. 84:102387.
- 203

Figure Legends

Figure 1. Associations between human milk oligosaccharides (HMOs) and malaria outcomes in children. **A.** Higher concentrations of α 1-2 fucose-linked HMOs, total and fucose-bound HMOs in mothers of malaria-free (MF) children. **B.** Higher concentrations of α 1-3- and α 1-4- fucose-linked HMOs and a sialylated HMO in mothers of malaria-infected (MI) children. **C.** Higher concentrations of LNT in mothers

of children with asymptomatic malaria (AM). **D.** Higher concentrations of DFLNT, FLNH and fucose-bound HMOs in mothers of children with severe malaria (SM). **E.** Higher diversity and concentrations of LNT in mothers of children with asymptomatic malaria. **F.** Higher concentrations of 2'FL, LNFP I and HMO-bound fucose in mothers of malaria-free children. Abbreviations: 2'FL, 2'fucosyllactose; LNFP I, lacto-N-fucopentaose I, 3'SL, 3'sialyllactose; DFLac, difucosyllactose; LNFP II, lacto-N-fucopentaose II (LNFP II), and LSTb, sialyllacto-N-tetraose b; LNT, lacto-N-tetraose; DFLNT, difucosyllacto-N-tetraose ; FLNH, fucosyllacto-N-hexaose; and Fuc HMO, HMO-bound fucose. Data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of HMO concentrations or diversity by malaria outcomes by either t-tests or Mann-Whitney U test. NS, non-significant; * Unadjusted P < 0.05; ** Unadjusted P < 0.01.

Figure 2. Sex-dependent associations between HMOs and malaria outcomes in children. **A.** Higher concentrations of 2'FL and fucose-bound HMOs in milk of mothers of malaria-free (MF) female children. **B.** Higher diversity and concentrations of LNFP II and LSTb in mothers of malaria-infected (MI) male and female children, respectively. **C.** Higher concentrations of LNT and fucose-bound HMOs in mothers of male children with asymptomatic (AM) and clinical malaria (MM+SM). **D.** Higher diversity and concentrations of LNT in mothers of AM female children. **E.** Higher concentrations of LNFP I, HMO-bound fucose and DSLNT in mothers of male and female children with MF status. Abbreviations: F, females; M, males. DSLNT, disialyllacto-N-tetraose; 2'FL, 2'fucosyllactose; LNFP I, lacto-N-fucopentaose I; LNFP II, lacto-N-fucopentaose II (LNFP II), and LSTb, sialyllacto-N-tetraose b; LNT, lacto-N-tetraose; Fuc HMO, HMO-bound fucose. Data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of HMO concentrations or diversity by malaria outcomes by either t-tests or Mann-Whitney U test. NS, non-significant; * Unadjusted P < 0.05; ** Unadjusted P < 0.01.






A**B****C****D****E**

Figure 2. Associations between HMOs and malaria outcomes in female and male children







A**B****C****D****E****F**

Figure 1: Associations between HMOs and malaria outcomes in all children